DiabetesSeriesLive

CME Presentations

Cardiovascular Disease, Diabetes, and Diabetes Treatments


Presentations

  • CME
    1.0

    Diabetes and Cardiovascular Disease: What are the Issues?

    Speakers:Donald E. Cutlip, MD, Section Chief, Interventional Cardiology
    Richard Beaser, MD, Senior Physician, Medical Director, Professional Education
    Vivian A. Fonseca, MD, FRCP, Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Duration: 60 minutes

    Presented on: March 1, 2017

  • CME
    1.0

    Cardiovascular Disease and Diabetes Medications: Analyzing the Outcome Studies and Understanding their Implications

    Speakers:Donald E. Cutlip, MD, Section Chief, Interventional Cardiology
    Richard Beaser, MD, Senior Physician, Medical Director, Professional Education
    Robert E. Heinig, MD, Director, Vascular Disease Prevention Program
    Vivian A. Fonseca, MD, FRCP, Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Duration: 60 minutes

    Presented on: March 1, 2017

  • CME
    1.0

    Cardiovascular Disease and Diabetes Medications: Applying Trial Outcomes to Clinical Practice

    Speakers:Michael Rocco, MD, Medical Director of Stress Testing and Cardiac Rehabilitation
    Richard Beaser, MD, Senior Physician, Medical Director, Professional Education
    Stephen A. Brunton, MD, FAAFP, Executive Vice President
    Om P. Ganda, MD, Medical Director of the Lipid Clinic, Chair of the Clinical Oversight Committee

    Duration: 60 minutes

    Presented on: March 29, 2017


Speakers

  • Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Section Chief, Interventional Cardiology

    Donald E. Cutlip, MD, is section chief of interventional cardiology and director of the Cardiac Catheterization Laboratory at Beth Israel Deaconess Medical Center, professor of medicine at Harvard Medical School, and a senior investigator at the Baim Institute for Clinical Research in Boston, Massachusetts. His clinical activities focus on coronary and valvular interventions, with a special interest in cardiovascular disease in patients with diabetes. He is involved in the design and management of numerous clinical trials of coronary, valvular, and peripheral vascular interventions. Dr Cutlip founded the Academic Research Consortium, and was a member of the ACC/AHA Task Force’s writing committee for key data elements and definitions for cardiovascular endpoint events in clinical trials.
  • Richard Beaser, MD

    Richard Beaser, MD

    Richard Beaser, MD

    Senior Physician, Medical Director, Professional Education

    Richard S. Beaser, M.D., is a practicing physician in the Joslin Clinic and holds the position of Associate Clinical Professor of Medicine at Harvard Medical School. He has also been the Medical Executive Director of Professional Education at Joslin and was instrumental in developing that activity at Joslin, a department he founded in 1990. Dr. Beaser graduated in 1973 from Trinity College, Hartford, and received his medical degree from Boston University School of Medicine in 1977. He served as a resident in internal medicine at the University of Massachusetts Medical Center in Worcester from 1977-1980. He was a fellow in endocrinology at the Joslin Diabetes Center, Boston, MA 1980-81, and in Endocrinology at the Lahey Clinic Medical Center, Burlington, MA 1981-82. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982. He has held numerous past positions at Joslin, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, Coordinator of the Patient Education Section, and Medical Director of Joslin TrialNet, a clinical trials network. He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial. Dr. Beaser has authored 4 books: Joslin Diabetes Manual, Outsmarting Diabetes, The Joslin Guide to Diabetes, and Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers. Dr Beaser is a well-known national lecturer on clinical diabetes and its comorbidities. He is the author of numerous publications in peer review journals, review articles, and book chapters. In his role as Medical Executive Director of Professional Education at Joslin Diabetes Center, and currently as the Chair of the CME Committee, Dr. Beaser has a specific focus on development or oversight of educational content for the department, targeting physicians, other medical professionals, and patients. He leads departmental conceptualization and development of projects and activities.
  • Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Vivian A. Fonseca, MD, FRCP, is a professor of medicine and pharmacology, the Tullis-Tulane Alumni Chair in Diabetes, and chief, Section of Endocrinology, at Tulane University Health Sciences Center in New Orleans, Louisiana. His current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. Dr Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London) and the American College of Physicians, and is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on numerous national and international committees, and has published more than 200 papers, review articles and book chapters.
  • Robert E. Heinig, MD

    Robert E. Heinig, MD

    Robert E. Heinig, MD

    Director, Vascular Disease Prevention Program

    Robert E. Heinig, MD, is clinical professor of medicine at the University of Rochester Medical School and director of the Vascular Diabetes Prevention Program at Rochester General Hospital in Rochester, New York. His current research interests include genetic and disease-related hyperlipidemia, normocholesterolemic dyslipidemia in insulin-resistant patients predisposing to coronary heart disease, and multiple risk factor modification in diabetic and insulin resistant patients with coronary heart disease. He belongs to several professional societies, including the American Diabetes Association, Endocrine Society, the American Society of Nephrology, and the American Association of Clinical Endocrinologists. Dr Heinig earned his MD from the University of Oregon School of Medicine in Portland.
  • Michael Rocco, MD

    Michael Rocco, MD

    Michael Rocco, MD

    Medical Director of Stress Testing and Cardiac Rehabilitation

    Michael Rocco, MD, is medical director of Cardiac Rehabilitation and Stress Testing, section of preventive cardiology, and a staff physician in the Departments of Cardiovascular Medicine and Molecular and Functional Imaging in the Division of Radiology at Cleveland Clinic in Ohio. His clinical research focuses primarily on the prognostic significance of asymptomatic ischemia, the evaluation of therapeutic interventions and exercise in the treatment and prevention of coronary artery disease, and the effect of drug therapy on lowering lipid levels. Dr Rocco lectures regionally and nationally, has published articles and abstracts in leading medical journals, and has authored chapters in textbooks. He received his medical degree from Duke University Medical Center in Durham, North Carolina.
  • Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Executive Vice President

    Stephen Brunton, MD, FAAFP, is the executive vice president for education for the Primary Care Education Consortium, works in a group practice in Los Angeles, California, and is an adjunct clinical professor in the Department of Pharmacy Practice at Roseman University of Health Sciences in Salt Lake City, Utah. A board-certified family physician with a certificate of added qualifications in geriatrics, he earned his MD at Monash University Medical School in Melbourne, Australia. He is the former president of the California Academy of Family Physicians and the Association of Family Medicine Residency Directors. Dr Brunton has published numerous articles, chapters, and monographs on family medicine and related clinical topics, and serves in editorial capacities for numerous journals.
  • Om P. Ganda, MD

    Om P. Ganda, MD

    Om P. Ganda, MD

    Medical Director of the Lipid Clinic, Chair of the Clinical Oversight Committee

    Om P. Ganda, MD, FACE, is a board-certified specialist in internal medicine, endocrinology and metabolism, and clinical nutrition. He is a senior physician at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts. A co-investigator in the Diabetes Control and Complications Trial (DCCT), he has been engaged in clinical diabetes research for more than 3 decades. He is co-investigator of Epidemiology of Diabetes Interventions and Complications (EDIC), an ongoing, long-term, follow-up study. In addition to his clinical research and teaching, he directs the Lipid Clinic at Joslin, where he treats complex patients with dyslipidemia. Dr Ganda received his MD from the SMS Medical College, University of Rajasthan, Jaipur, India.

CME Information

Cardiovascular Disease, Diabetes, and Diabetes Treatments: Understanding the Interrelationships Jointly Provided by the University of Cincinnati and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT This activity is supported by educational grants provided by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC, and Novo Nordisk Inc. TUITION Complimentary

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and PlatformQ Health Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION Live Internet Activity The University of Cincinnati designates this Live Activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material The University of Cincinnati designates this Enduring Material Activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION Live Activity March 1, 2017 from 12:00 PM EST – 2:00 PM EST (Sessions 1 and 2) March 29, 2017 from 11:00 AM EST – 12:00 PM EST (Supplementary session)

Enduring Material The enduring material will be available from March 1, 2017 – September 29 2017.

ACTIVITY DESCRIPTION Type 2 diabetes mellitus is associated with substantially increased cardiovascular risk. Evidence-based recommendations include recommendations to address cardiovascular risk factors and end-organ impact as important components of treatment. In addition, it has been established that factors impacting cardiovascular outcomes go beyond glycemic control itself in these high-risk patients. Multiple studies have demonstrated these interrelationships and the need for a comprehensive, multifaceted treatment approach for patients with diabetes. However, interventions impacting surrogate markers of end-organ cardiovascular damage may not necessarily reduce end-organ damage and improve cardiovascular outcomes. Thus the cardiovascular impact of antidiabetes medications has become the focus. A number of clinical trials over the last few years have been conducted with cardiovascular outcomes as part of the protocol. Applying the findings from these studies is challenging. Understanding the impact of these new mediations on the pathophysiology of cardiovascular disease is needed as well as the ability to differentiate among effects of class compared with drug-specific effects. Study design may also impact outcomes in multiple ways. Educational support from expert faculty is needed to guide the busy clinician through the complexities of these issues. This program will enable leading experts to discuss the interrelationship and clinical implications between type 2 diabetes, the cardiometabolic syndrome and cardiovascular disease as well as the role of diabetes medications on cardiovascular risk. The goal of this educational initiative is to empower clinicians to more fully understand and critically assess these studies and appropriately utilize them when making therapeutic decisions with the ultimate goal to improve patient outcomes.

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Discuss the etiologic and pathophysiologic interconnections among the components of the cardiometabolic syndrome and the development of cardiovascular disease
Identify pharmacological actions of antidiabetes medications that could potentially impact cardiovascular outcomes
Describe the rationale for studying the cardiovascular impact of antidiabetes medications
Compare and contrast antidiabetes pharmacotherapies which can optimize glycemic control and minimize adverse effects on cardiovascular risk and/or disease
Discuss the efficacy and safety data for recent trials that examined the cardiovascular impact of antidiabetes medications
Demonstrate critical assessment of recent cardiovascular outcomes trials for antidiabetes medications in making evidence-based selections and usage decisions for clinical care

TARGET AUDIENCE This activity is intended for primary care clinicians, diabetes specialists, cardiologists, as well as other health care providers who provide front-line glycemic management for type 2 diabetes (T2DM) and its comorbidities.

ESTIMATED TIME TO COMPLETE This activity consists of three sessions, each of which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to http://www.diabetesserieslive.com/ or http://www.cardiocarelive.com/. To receive credit, participants must (1) read the CME information, including the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. This activity consists of three sessions, each of which will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters Disclosures:
Richard S. Beaser, MD – Program Course Chair and Moderator

Dr Beaser has no financial relationships to disclose.

Stephen A. Brunton, MD, FAAFP

Advisory Board: Novo Nordisk; BI Lilly; Sanofi, Janssen, AstraZeneca; Intarcia Therapeutics, Inc.; Becton Dickinson Consultant: Novo Nordisk; Lilly; Sanofi; Janssen; Intarcia Therapeutics, Inc.; Becton Dickinson Speaker's Bureau: Novo Nordisk; BI Lilly; Janssen; AstraZeneca

Donald E. Cutlip, MD

Grant recipient (self): CeloNova; Medtronic

Vivian A. Fonseca, MD, FRCP

Research Support (to Tulane): Novo Nordisk; Asahi; Eli Lilly; Abbott; Endo Barrier, Gilead Sciences Consulting and Lecturing Honoraria: Takeda; Novo Nordisk; sanofi-aventis; Eli Lilly; Pamlab; AstraZeneca; Abbott; Amgen; Boehringer Ingelheim; Janssen

Om P. Ganda, MD

Consultant: Novo Nordisk; Sanofi Grant recipient: Amarin Medical Lectures: Merck

Robert E. Heinig, MD

Advisory Board: Regeneron Pharmaceuticals Speaker's Bureau: Amgen; AstraZeneca; Janssen; Merck; Sanofi

Michael Rocco, MD

Dr Rocco has no financial relationships to disclose.

University of Cincinnati  
Susan P. Tyler, MEd, CMP, CHCP, CME Director

Has nothing to disclose.

Rick E. Ricer, MD, Professor Emeritus, CME Physician Reviewer

Has nothing to disclose.

Deborah Cole, Program Coordinator, UC Continuing Medical Education

Has nothing to disclose.

PlatformQ Health Education, LLC  
Karen Greb–Murphy, Program Manager

Has nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): The University of Cincinnati requires the presenters to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMER: The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material. The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Cincinnati, DiabetesSeriesLive, CardioCareLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION Accreditation Support: Please contact the University of Cincinnati Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277.

Technical Support: For any technical issues or issues with your CME Certificate, please contact DiabetesSeriesLive or CardioCareLive at 877-394-1306, or at Support@DiabetesSeriesLive.com or Support@CardioCareLive.com.